Ceftazidime-avibactam is a novel combination of a known cephalosporin and a non-β-lactam/β-lactamase inhibitor that has been approved for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia as well as Gram-negative infections with limited treatment options in Europe. Since its approval, it has been used in patients with infections due to carbapenem-resistant bacteria, in many occasions as off-label indication or salvage therapy, with promising clinical and microbiological cure rates. Emergence of resistance during therapy to this new combination has already been described, which is a matter of concern. A rational use of these new therapeutic options is critical in the multidrug resistance era. The current review focuses on the clinical experience in real life of ceftazidime-avibactam use in the treatment of carbapenemase-producing Enterobacterales.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fmb-2020-0012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and mortality associated with multidrug-resistant infections in adult intensive care units in Argentina (PREV-AR).
Antimicrob Agents Chemother
January 2025
Argentinian Society for Critical Care (SATI), Buenos Aires, Buenos Aires, Argentina.
Unlabelled: Data from low and middle-income countries (LMICs) on multidrug-resistant microorganisms (MDROs) in intensive care units (ICUs) are scarce. Working in several ICUs in Argentina, we sought to estimate the prevalence and characteristics of MDRO infections and carbapenemase-producing Enterobacterales (CPE) colonization. Mortality associated with MDRO infection was also evaluated.
View Article and Find Full Text PDFHigh prevalence of fecal carriage of extended-spectrum beta-lactamase producing among patients with urinary tract infections in rural Tanzania.
Front Microbiol
January 2025
Medical Research Center, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Introduction: The global rise of extended-spectrum beta-lactamase-producing (ESBL-PE) challenges resource-limited countries with insufficient laboratory infrastructure. This study investigates fecal carriage and risk factors for ESBL-PE and carbapenemase-producing organisms among patients with urinary tract infection (UTI) in rural Tanzania.
Methods: This cross-sectional study was conducted at St.
MALDI biotyper - Phenotypic identification test rapid assay (MBT-PITRA): A new method to detect KPC and NDM in Enterobacterales.
J Microbiol Methods
January 2025
Faculdade de Farmácia, Universidade Federal do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil; Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas (PPGCF), Faculdade de Farmácia, Universidade Federal do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil. Electronic address:
Carbapenemase-producing Enterobacterales are a growing concern in public health. In order to rapidly determine the antimicrobial profile, the MALDI Biotyper - antibiotic susceptibility test rapid assay (MBT-ASTRA) was developed, based on the relative growth of bacteria in the presence of antibiotics. In this study, we added carbapenemase enzymatic inhibitors to the MBT-ASTRA and developed an adapted method named MALDI Biotyper - Phenotypic Identification Test Rapid Assay (MBT-PITRA) in order to perform a rapid and cost-effective phenotypic test to detect Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-beta-lactamase (NDM), including co-producers, in Enterobacterales.
View Article and Find Full Text PDFCarbapenemase-Producing Enterobacterales: An Increasing Threat to Australian Liver Transplant Recipients.
Transpl Infect Dis
January 2025
Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Introduction: Carbapenemase-producing Enterobacterales (CPE) are associated with increased morbidity and mortality in liver transplant recipients (LTRs). There is a paucity of data regarding CPE colonization and infection in Australian LTRs.
Methods: A single-center retrospective cohort study of CPE was performed in LTRs from 2015 to 2024.
Characterization of Enterobacterales growing on selective CPE screening plates with a focus on non-carbapenemase-producing strains.
Microbiol Spectr
January 2025
National Institute for Antibiotic Resistance and Infection Control, Israel Ministry of Health, Tel Aviv, Israel.
Unlabelled: Carbapenem-resistant Enterobacterales (CRE) are divided into two distinct groups: carbapenemase-producing (CPE) and non-carbapenemase-producing (non-CPE). The population of non-CPE growing on CPE selective plates during routine screening is usually not reported and is not well defined. This study aimed to characterize non-CPE isolates growing on those plates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!